# US 2022/0031798 A1 · Methods and compositions for the treatment of opioid dependence and for the treatment of pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031798 A1
- Document ID: US20220031798A1
- Status: Published application
- Kind: A1
- Application number: 17/298,664
- Filed: 2019-12-04
- Published: 2022-02-03
- Earliest claimed: 2018-12-04
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Ashwin Patkar; Cynthia Kuhn
- Web page: https://patentgrep.com/patent/US20220031798A1

## CPC

- A61K 38/07: Tetrapeptides
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods of treating opioid dependence, enhancing the treatment of opioid dependence, treating opioid withdrawal, or alleviating one or more opioid withdrawal symptoms in a subject, preventing or reducing the likelihood of opioid dependence relapse in a subject treated for opioid dependence, reducing the vulnerability of a subject to develop opioid dependence in adulthood following opioid exposure during adolescence, or treating pain in a subject, comprising administering a therapeutically effective amount of a N-methyl-D-aspartate receptor (NMDA) partial agonist to the subject. The present invention further relates to compositions comprising an NMDA partial agonist for use with the aforementioned methods.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

A method of treating hyperalgesia in a subject, the method comprising: administering a therapeutically effective amount of a NMDA partial agonist to the subject.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

A method of reducing the vulnerability of a subject to develop opioid dependence in adulthood following opioid exposure during adolescence, the method comprising: administering a therapeutically effective amount of a NMDA partial agonist to the subject.

### Claim 9

(canceled)

### Claim 10 (depends on 4)

The method according to claim 4 wherein the NMDA partial agonist is rapastinel.

### Claim 11 (depends on 4)

The method according to claim 4 wherein the subject is a human.

### Claim 12 (depends on 11)

The method according to claim 11 wherein the human is an adolescent.

### Claim 13

A composition comprising an NMDA partial agonist and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The composition of claim 13 wherein the NMDA partial agonist is rapastinel.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 11)

The method according to claim 11, wherein the human is an adult.

### Claim 28 (depends on 4)

The method according to claim 4, wherein the subject has an opioid dependence.

### Claim 29 (depends on 4)

The method according to claim 4, wherein the NMDA partial agonist comprises N-methyl-D-aspartic acid, 3,5-dibromo-L-phenylalanine, apimostinel, aminocyclopropanecarboxylic acid, cycloserine, HA-966, NYX-2925, or homoquinolinic acid.

### Claim 30 (depends on 4)

The method according to claim 4, further comprising: repeating the administering step.

### Claim 31 (depends on 4)

The method according to claim 4, further comprising: preventing opioid dependence relapse.

### Claim 32 (depends on 8)

The method according to claim 8, wherein the NMDA partial agonist is rapastinel.

### Claim 33 (depends on 8)

The method according to claim 8, wherein the NMDA partial agonist comprises N-methyl-D-aspartic acid, 3,5-dibromo-L-phenylalanine, apimostinel, aminocyclopropanecarboxylic acid, cycloserine, HA-966, NYX-2925, or homoquinolinic acid.

### Claim 34 (depends on 8)

The method according to claim 8, further comprising: repeating the administering step.

### Claim 35 (depends on 8)

The method of according to claim 8, further comprising: treating hyperalgesia in the subject.

### Claim 36 (depends on 8)

The method according to claim 8, further comprising: preventing opioid dependence relapse.

### Claim 37 (depends on 8)

The method according to claim 8, wherein the subject is a human.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the human is an adolescent.

### Claim 39 (depends on 37)

The method according to claim 37, wherein the human is an adult.
